NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Fiscal quarter and nine months ended March 31, 2024; filed May 14, 2024. The supplied filing is for 2024 Q3, despite the request metadata referring to 2023 Q3. NanoViricides is a clinical-stage antiviral drug developer with no product sales or revenue.
Financial performance and position
| Metric | Three months ended Mar. 31, 2024 | Nine months ended Mar. 31, 2024 | Comparable 2023 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $1.215 million | $4.255 million | $1.196 million; $3.479 million |
| General and administrative expense | $694,000 | $1.870 million | $615,000; $1.788 million |
| Net loss | $1.854 million | $5.938 million | $1.703 million; $5.019 million |
| Loss per common share | $0.16 | $0.51 | $0.15; $0.43 |
| Operating cash used | Not separately reported | $4.834 million | $4.171 million |
Gross margin is not meaningful because the company had no revenue. At March 31, 2024, cash and cash equivalents were $3.257 million, current assets were $3.516 million, current liabilities were $813,000, total liabilities were $813,000, and stockholders’ equity was $10.652 million. The company reported no revenue and no anticipated revenue in the foreseeable future. It had an accumulated deficit of $137.0 million.
Cash declined $4.893 million from June 30, 2023. Investing cash use was $58,000 for property and equipment; there were no financing cash flows in the nine-month period. The $2 million related-party credit line had not been drawn at quarter-end. The prior-year $1.5 million milestone liability was converted into Series A preferred shares in October 2023; the related $49,808 accrued interest was forgiven.
Changes versus the prior comparable period
- Nine-month operating expenses increased $858,000: R&D rose $776,000, attributed to outside lab and clinical-trial costs; G&A rose $82,000, attributed to professional fees.
- Nine-month net loss increased $920,000, while operating cash use increased $663,000.
- Cash fell from $8.150 million at June 30, 2023 to $3.257 million at March 31, 2024. Total liabilities declined from $2.034 million, principally following conversion of the related-party milestone note.
- Common shares outstanding increased to 11.814 million from 11.698 million at June 30, 2023; Series A preferred shares increased to 892,238 from 547,674.
Business developments, outlook, and risks
- Lead program: NV-387, the active ingredient in NV-CoV-2, completed the healthy-subject portion of a Phase 1a/1b trial in India. The company reported no adverse events and said the drug was tolerated at tested doses. A final trial report and human pharmacokinetic analyses were still pending. The planned COVID-patient portion could not enroll participants and the study was closed in April 2024; the filing says it generated no clinical evidence of activity against COVID.
- Planned development: Management is prioritizing NV-387 for RSV, including preparing a U.S. FDA pre-IND submission and a potential Phase II trial application. The company also discusses further development for influenza and poxvirus infections, but these plans depend on regulatory review, study results, and financing. The company provides no numerical financial guidance or assured clinical timelines.
- Other pipeline: NV-HHV-1, a shingles cream candidate, is planned for clinical development after NV-387’s RSV program. Other antiviral candidates remain at earlier stages. Efficacy statements in the filing largely describe preclinical or animal research, not established human efficacy.
- Going concern: Management states that existing resources, including the undrawn credit line, will not fund planned operations for at least 12 months from filing and that substantial doubt exists about the company’s ability to continue as a going concern. The company expects continued losses and depends on additional financing, expense control, grants, licensing, or other partnerships; none is assured.
- Financing actions: An at-the-market agreement with EF Hutton became active around April 15, 2024, after quarter-end. Management also said it was seeking mortgage financing secured by its Shelton campus and manufacturing facilities. The CEO’s $2 million credit line bears 12% interest if drawn and is secured by company property and equipment.
- Related parties: TheraCour, controlled by CEO Anil Diwan, supplies licensed technology and development services; the company reports $213,148 payable to TheraCour and $588,763 of related-party R&D costs for the quarter. The company generally owes TheraCour 15% of net sales upon commercialization. KMPL, in which Diwan is a passive investor and advisor, sponsored the India trial; the company pays trial costs plus a 30% manager fee and would receive 70% of specified sales after third-party costs.
- Controls and legal matters: Management concluded disclosure controls were ineffective at March 31, 2024 because of an unremediated material weakness concerning timeliness of financial reporting review. The company reported no pending or threatened material legal proceedings to its knowledge.
Key facts for investors to verify
- Current cash runway, actual spending after March 31, and whether financing has been obtained on acceptable terms; the filing explicitly identifies a substantial going-concern doubt.
- Whether the Phase 1 final report and pharmacokinetic results are available, and what regulatory feedback and funding would be required to advance NV-387 into RSV trials.
- Whether any clinical evidence supports efficacy: the reported Phase 1 study had no enrolled COVID patients, while the reported antiviral efficacy claims are primarily preclinical or animal findings.
- Terms, availability, and potential dilution from the ATM facility, any mortgage financing, and the CEO’s secured credit line; confirm whether any related-party borrowing has occurred since quarter-end.
- Related-party licensing, development fees, and governance safeguards, including the CEO’s relationships with TheraCour and KMPL.
- Progress and timing of remediation of the financial-reporting material weakness, and the company’s ability to meet future filing deadlines.